• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • Our Technology
      • TIM
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Exposition

November 4, 2021 By Celyad Oncology

  • Two abstracts will be presented in a pre-recorded poster presentation and oral session

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that two abstracts have been accepted for a poster presentation and an oral session at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in person in Atlanta, Georgia and virtually from December 11-14, 2021. The poster will focus on the Company’s shRNA-based anti-BCMA allogeneic CAR T candidate CYAD-211 for the treatment of relapsed/refractory (r/r) multiple myeloma (r/r MM). The oral session will focus on the Company’s autologous NKG2D receptor-based CAR T candidate CYAD-02 for the treatment of r/r acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In addition, the abstracts will be published online in the November supplemental issue of peer-reviewed journal Blood.

ASH 2021 Presentation Details:

The following abstracts published today are now available on the ASH conference website. Following their presentation at the meeting, the posters will be available in the Scientific Publications section of Celyad Oncology’s website.

Publication #2817:            IMMUNICY-1: Targeting BCMA with CYAD-211 to Establish Proof Of Concept of An shRNA-based Allogeneic CAR T Cell Therapy Platform

Session Name:                  704. Cellular Immunotherapies: Clinical: Poster II – Poster presentation

Date:                                    Sunday, December 12, 2021, from 6:00 p.m. to 8:00 p.m. ET

Location:                             Georgia World Congress Center, Hall B5

Publication #408:              Co-expression of an shRNA Targeting MICA/MICB Improves the Clinical Activity of a NKG2D-based CAR T In Patients with Relapsed / Refractory AML/MDS

Session Name:                  703. Cellular Immunotherapies: Basic and Translational II – Oral session

Date:                                    Sunday, December 12, 2021

Presentation Time:            10:45 a.m. ET

Location:                             Georgia World Congress Center, Room B405-407

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Uncategorized

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use